Both of these funds target U.S. small-cap equities, but they pursue that goal through materially different methods, making them a useful ETF comparison for investors building a core domestic allocation. FNDA filters and weights companies by fundamental size rather than market value, introducing a value tilt and a contrarian rebalancing discipline. SCHA, by contrast, tracks a broad market-cap-weighted small-cap index, aiming to capture the segment as a whole. Because they serve overlapping investor goals but deliver distinct sector exposure and risk profiles, evaluating their relative positioning is especially timely as small-cap leadership rotates and interest rate expectations shift.
FNDA is a passively managed, fundamentally weighted ETF that tracks the RAFI Fundamental High Liquidity U.S. Small Index. The RAFI methodology selects and weights companies using fundamental metrics — adjusted sales, retained operating cash flow, and dividends plus buybacks — rather than market capitalization. This approach produces a built-in value tilt and disciplined, rules-based rebalancing that trims holdings that have grown expensive and adds to those that have become cheaper. When I reviewed the holdings, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The fund holds approximately 900 stocks, with top positions including LITE (Lumentum), AMKR (Amkor Technology), COHR (Coherent), MKSI (MKS Instruments), and VSAT (Viasat). Its sector allocation is led by industrials (roughly 19%), followed by financial services, technology, and consumer discretionary, with notable exposure to real estate and energy. The expense ratio is 0.25%, and the fund carries a weighted average market capitalization in the small-to-mid range, giving it a somewhat larger-cap profile than many pure small-cap peers.
SCHA is a passively managed, market-cap-weighted ETF that seeks to track the Dow Jones U.S. Small-Cap Total Stock Market Index, which covers U.S. stocks ranked roughly 751 to 2,500 by market capitalization. This broad mandate delivers exposure across the small-cap spectrum without a profitability or fundamental screen, making it a straightforward "total small-cap" building block.
The fund holds approximately 1,700 securities, an extremely diversified portfolio in which the top ten positions account for only a small single-digit percentage of assets. Prominent holdings include SNDK (SanDisk), LITE (Lumentum), RVMD (Revolution Medicines), and Guardant Health. Sector exposure is led by technology (about 20%), followed by financial services, healthcare, and industrials, with consumer cyclical and real estate completing the top tier. SCHA's expense ratio is just 0.03%, among the lowest available in the small-cap category, and it has amassed substantial assets under management (AUM), supporting strong liquidity and tight bid-ask spreads.
U.S. small caps sit at the intersection of several powerful macro forces. Interest rate policy remains the dominant driver: smaller companies typically carry more floating-rate or refinanceable debt, so shifting rate expectations influence their funding costs and valuations directly. At the same time, a broadening of market leadership beyond a handful of mega-cap technology names has directed renewed capital flows into smaller, domestically oriented businesses. Sector-level catalysts matter too — semiconductor and hardware-linked names, which feature in both funds, respond to artificial intelligence infrastructure spending and cyclical demand, while financials benefit from changes in the yield curve and regional banking conditions. Key risks include a slowing economy, sticky inflation, and earnings volatility among less-established companies, all of which can magnify small-cap drawdowns relative to large caps.
Over recent weeks and months, both funds have participated in the broader small-cap rally, but their relative performance has diverged along sector lines. SCHA's heavier technology and healthcare weighting has aligned it with momentum in AI-related hardware and biotechnology, while its growth-oriented composition has made it somewhat more volatile and prone to deeper drawdowns during risk-off stretches. FNDA's fundamental weighting has kept it comparatively steadier, with its industrials, financials, and energy exposure providing ballast and a more defensive character during value-led rotations.
In terms of relative positioning, SCHA offers higher beta (sensitivity to market moves) and greater cyclical upside, whereas FNDA's value tilt and disciplined rebalancing tend to smooth extremes. Cost is also a persistent differentiator: SCHA's near-zero fee compounds favorably over time, while FNDA's higher fee must be justified by its factor-based return potential.
I often turn to Tickeron’s AI Screener when comparing ETFs like these, as it helps me quickly filter based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. This tool makes it straightforward to scan thousands of stocks and ETFs with customizable criteria such as industry, market capitalization, and performance metrics, surfacing ideas that align with a given strategy far more efficiently than manual work. From what I see, it adds useful context when evaluating holdings and sector tilts in real time.
Based on observable structural factors, Tickeron's AI would currently favor SCHA. Its 0.03% expense ratio is a durable, compounding advantage over FNDA's 0.25% fee, and its roughly 1,700-stock portfolio provides broader diversification that dilutes single-name risk. SCHA's greater exposure to technology and healthcare aligns with prevailing momentum and capital flows, and its trend consistency has remained resilient across recent market cycles. FNDA remains a compelling choice for investors specifically seeking a fundamental, value-oriented tilt with disciplined rebalancing, but on a blend of cost efficiency, diversification, and sector momentum, SCHA currently holds the edge in this matchup.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The 10-day moving average for SCHA crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SCHA as a result. In 74 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for SCHA turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
SCHA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The RSI Indicator entered the oversold zone -- be on the watch for SCHA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCHA advanced for three days, in 269 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
SCHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 223 of 270 cases where SCHA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows